Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Clinical trial NCT06806046 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06806046
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-20
- Primary completion
- 2026-09-30
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.